New inhaler treatment aims to boost oxygen in COPD lungs
NCT ID NCT07037836
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether an inhaled drug called treprostinil (Tyvaso) can improve oxygen delivery in the lungs of people with COPD who have low blood oxygen. Ten adults will use the nebulizer four times daily for four weeks, starting at a low dose and increasing as tolerated. Researchers will use special MRI scans to measure changes in lung blood flow and oxygen exchange before and after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Inhaled treprostinil (Tyvaso nebulizer)
What this could lead to
If it works, this could point toward a new treatment to improve oxygen delivery and lung function in COPD patients with low blood oxygen.
What could go wrong
This is a very small, early-phase trial with only 10 participants, so results may not apply to everyone. The drug may cause side effects and may not show clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOXEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke Asthma Allergy and Airway Center
RECRUITINGDurham, North Carolina, 27705, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact